Fulcrum Therapeutics director reports zero share ownership

Fulcrum Therapeutics, Inc. director Joshua Lehrer-Graiwer filed an initial ownership report indicating that he currently holds no company securities.

Rhea-AI Filing Summary

Fulcrum Therapeutics, Inc. director Joshua Lehrer-Graiwer filed an initial ownership report indicating that he currently holds no company securities. The filing shows zero shares directly owned following the reported holding entry, meaning he reports no beneficial ownership of Fulcrum Therapeutics stock at this time.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Lehrer-Graiwer Joshua

Role Director

Type	Security	Shares	Price	Value
holding	No securities are beneficially owned	--	--	--

Holdings After Transaction: No securities are beneficially owned — 0 shares (Direct)

Key Figures

Shares beneficially owned: 0 shares

1 metrics

Shares beneficially owned 0 shares Total shares following holding entry on April 23, 2026

Key Terms

Form 3, beneficially owned, reporting person

3 terms

Form 3 regulatory

"INSIDER FILING DATA (Form 3)"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

beneficially owned financial

"security_title: "No securities are beneficially owned""

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

reporting person regulatory

""reportingPersons": [ { "name": "Lehrer-Graiwer Joshua""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Fulcrum Therapeutics (FULC) Form 3 for Joshua Lehrer-Graiwer show?

The Form 3 shows that director Joshua Lehrer-Graiwer reports no beneficial ownership of Fulcrum Therapeutics, Inc. securities. The filing lists zero shares directly owned following the holding entry dated April 23, 2026, establishing his initial ownership baseline as a director.

Does Fulcrum Therapeutics (FULC) director Joshua Lehrer-Graiwer own any shares?

According to the Form 3, director Joshua Lehrer-Graiwer reports owning zero shares of Fulcrum Therapeutics, Inc. common stock. The filing states “No securities are beneficially owned,” with total shares following the reported holding shown as 0.0000, all classified as direct ownership.

Is the Fulcrum Therapeutics (FULC) Form 3 a buy or sell transaction?

The Form 3 for Joshua Lehrer-Graiwer does not report any buy or sell transactions. It is an initial ownership filing that records a holding entry with an unknown transaction code and confirms zero shares beneficially owned, establishing his starting position as a company director.

What is the significance of reporting zero beneficial ownership on a Form 3 for FULC?

Reporting zero beneficial ownership on a Form 3 means the insider currently holds no reportable Fulcrum Therapeutics, Inc. securities. It sets an official baseline for future Forms 4 or 5, so any later acquisitions, dispositions, or grants can be measured against today’s zero-share starting point.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/01/2026 - 04:10 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Lehrer-Graiwer Joshua

(Last) (First) (Middle)

C/O FULCRUM THERAPEUTICS, INC.

26 LANDSDOWNE STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02139

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
04/23/2026

3. Issuer Name and Ticker or Trading Symbol
Fulcrum Therapeutics, Inc. [ FULC ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
No securities are beneficially owned	0	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit Index: 24.1 Power of Attorney

	/s/ Alan Musso as attorney-in-fact for Joshua Lehrer-Graiwer	05/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)